Brief: Simcere Pharmaceutical Expects FY Adjusted Profit Attributable Near RMB1,003 Mln To RMB1,033 Mln
21/02/2025 01:26
Feb 21 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* EXPECTS FY24 ADJUSTED PROFIT ATTRIBUTABLE OF NEAR RMB1,003
MILLION TO RMB1,033 MILLION
* SEES FY2024 REVENUE OF ABOUT RMB6,620 MILLION TO RMB6,650
MILLION
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660